Brucellosis is a widespread zoonotic bacterial infection that affects over 500,000 people annually, with significant economic losses in the livestock industry, particularly in endemic regions such as the Middle East, Asia, and parts of Africa and Latin America. Despite standard antibiotic treatments, relapse rates remain as high as 10%–15%, highlighting the limitations of current therapeutic options.
Objective:
Phage therapy, which uses bacteriophages to selectively target and lyse Brucella spp. bacteria, offers a promising approach for managing brucellosis.
Methods:
This paper explores the current understanding of brucellosis, highlighting the impact on animal and human health, and reviews the mechanisms and efficacy of bacteriophages against Brucella spp.Results:Key factors, such as phage specificity, immune modulation, and recent advancements in phage encapsulation, are discussed as strategies to enhance treatment efficacy.
Conclusion:
This review aims to explore emerging alternative therapies beyond conventional antibiotics, focusing on approaches such as immunotherapy, bacteriophage therapy, and novel vaccine strategies to improve clinical outcomes and reduce disease burden.
AghaeeBL, Khan MirzaeiM, AlikhaniMY, et al.Improving the inhibitory effect of phages against Pseudomonas aeruginosa isolated from a burn patient using a combination of phages and antibiotics. Viruses, 2021; 13(2):334.
2.
AkokoJ, PelleR, KivaliV, et al.Serological and molecular evidence of Brucella species in the rapidly growing pig sector in Kenya. BMC Vet Res, 2020; 16(1):133–137.
3.
AlaidarousM, VeT, CaseyLW, et al.Mechanism of bacterial interference with TLR4 signaling by Brucella Toll/interleukin-1 receptor domain-containing protein TcpB. J Biol Chem, 2014; 289(2):654–668; doi: 10.1074/jbc.M113.523274
4.
AntadzeI, DadunashviliM, GuniaS, et al.Diversity of phage-host specificity in Brucella phage. J Bacteriol Mycol, 2017; 4:1049.
5.
BahadorA, HadjatiJ, HassannejadN, et al.Frequencies of CD4+ T regulatory cells and their CD25(high) and FoxP3(high) subsets augment in peripheral blood of patients with acute and chronic brucellosis. Osong Public Health Res Perspect, 2014; 5(3):161–168; doi: 10.1016/j.phrp.2014.04.008
6.
BasdewI, LaingM. 2011. Mini-Review: Biological control of bovine mastitis using bacteriophage therapy. Science Against Microbial Pathogens: Communicating Current Research and Technological Advances, Formatex Research Center; 386–393.
7.
Bhargava K, Nath G, Aseri GK, Jain N. Potential of bacteriophage therapy: a double edge sword to combat COVID-19 and associated pulmonary bacterial infections. Ind J Pharm Sci. 2021 Nov 1;83(6):1081–93.
8.
BurrowesB, HarperDR, AndersonJ, et al.Bacteriophage therapy: Potential uses in the control of antibiotic-resistant pathogens. Expert Rev Anti Infect Ther, 2011; 9(9):775–785.
9.
CampbellA. The future of bacteriophage biology. Nat Rev Genet, 2003; 4(6):471–477.
10.
CasabuonoAC, CzibenerC, Del GiudiceMG, et al.New features in the lipid A structure of Brucella suis and Brucella abortus lipopolysaccharide. J Am Soc Mass Spectrom, 2017; 28(12):2716–2723.
11.
CinquerruiS, MancusoF, VladisavljevićGT, et al.Nanoencapsulation of bacteriophages in liposomes prepared using microfluidic hydrodynamic flow focusing. Front Microbiol, 2018; 9:2172.
12.
Conde-AlvarezR, Arce-GorvelV, IriarteM, et al.The lipopolysaccharide core of Brucella abortus acts as a shield against innate immunity recognition. PLoS Pathog, 2012; 8(5):e1002675.
13.
CorbelM, MorrisJ. Investigation of the effect of brucella-phage on the course of experimental infection with Brucella abortus. Br Vet J, 1980; 136(3):278–289.
14.
DeanAS, CrumpL, GreterH, et al.Global burden of human brucellosis: A systematic review of disease frequency. PLoS Negl Trop Dis, 2012; 6(10):e1865.
15.
DedrickRM, Guerrero-BustamanteCA, GarlenaRA, et al.Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus. Nat Med, 2019; 25(5):730–733.
16.
DiasSP, SequeiraJ, AlmeidaM. Spastic paraparesis and sensorineural hearing loss: Keep brucellosis in mind. J Neurol Sci, 2018; 385:144–145.
17.
DicksLM, VermeulenW. Bacteriophage–Host interactions and the therapeutic potential of bacteriophages. Viruses, 2024; 16(3):478.
18.
EsberHJ, DecourcySJ, BogdenAE. Specific and nonspecific immune resistance enhancing activity of staphage lysate. J Immunopharmacol, 1981; 3(1):79–92.
19.
FauconnierA. Phage therapy regulation: From night to dawn. Viruses, 2019; 11(4):352.
20.
FrancK, KrecekR, HäslerB, Arenas-GamboaA. Brucellosis remains a neglected disease in the developing world: A call for interdisciplinary action. BMC Public Health, 2018; 18(1):125–129.
21.
GłowackaP, ŻakowskaD, NaylorK, et al.Brucella–virulence factors, pathogenesis and treatment. Pol J Microbiol, 2018; 67(2):151–161.
22.
GodfroidJ, ScholzH, BarbierT, et al.Brucellosis at the animal/ecosystem/human interface at the beginning of the 21st century. Prev Vet Med, 2011; 102(2):118–131.
23.
GomezG, AdamsLG, Rice-FichtA, FichtTA. Host-Brucella interactions and the Brucella genome as tools for subunit antigen discovery and immunization against brucellosis. Front Cell Infect Microbiol, 2013; 3:17.
24.
GortázarC, FerroglioE, HöfleU, et al.Diseases shared between wildlife and livestock: A European perspective. Eur J Wildl Res, 2007; 53(4):241–256.
25.
GrillóM-J, BlascoJM, GorvelJP, et al.What have we learned from brucellosis in the mouse model?. Vet Res, 2012; 43(1):29; doi: 10.1186/1297-9716-43-29
26.
GroseJH, CasjensSR. Understanding the enormous diversity of bacteriophages: The tailed phages that infect the bacterial family Enterobacteriaceae. Virology, 2014; 468–470:421–443.
27.
HuffW, HuffG, RathN, et al.Evaluation of aerosol spray and intramuscular injection of bacteriophage to treat an Escherichia coli respiratory infection. Poult Sci, 2003; 82(7):1108–1112.
28.
HymanP. Phages for phage therapy: Isolation, characterization, and host range breadth. Pharmaceuticals, 2019; 12(1):35.
29.
IslamMS, HabibMA, TonuNS, et al.Beyond serology: A meta‐analysis of advancements in molecular detection of brucella spp. in Seronegative Animals and Biological Samples. Vet Med Sci, 2025; 11(1):e70200.
Lashtoo AghaeeB, AlikhaniMY, Van LeeuwenWB, et al.; Ramsar Campus, Mazandaran University of Medical Sciences, Ramsar, Iran. Conventional treatment of burn wound infections versus phage therapy. Iran J Med Microbiol, 2022; 16(3):186–196.
32.
LiC, WangY, PengQ. Research progress in the therapy of brucellosis. Animal Research and One Health, 2023; 1(1):127–136.
33.
LinJ, DuF, LongM, LiP. Limitations of phage therapy and corresponding optimization strategies: A review. Molecules, 2022; 27(6):1857.
34.
LiuH, JiangH. Advances in the application of molecular diagnostic techniques to brucellosis. Biomedical and Environmental Sciences, 2024; 37:790–794.
MatsuzakiS, RashelM, UchiyamaJ, et al.Bacteriophage therapy: A revitalized therapy against bacterial infectious diseases. Journal of Infection and Chemotherapy, 2005; 11(5):211–219.
37.
MaudlinI, WeberS. 2006. The Control of Neglected Zoonotic Diseases: A Route to Poverty Alleviation. WHO: Geneva.
38.
McdermottJ, GraceD, ZinsstagJ. Economics of brucellosis impact and control in low-income countries. Rev Sci Tech, 2013; 32(1):249–261.
39.
MirzaeiR, DehkhodaieE, BouzariB, et al.Dual role of microbiota-derived short-chain fatty acids on host and pathogen. Biomedicine & Pharmacotherapy, 2022; 145:112352.
40.
MohanA, SaxenaHM. Effect of phage targeting therapy of brucellosis on host antibody response in cattle. Phage (New Rochelle), 2020a;1(4):223–229; doi: 10.1089/phage.2020.0018
41.
MohanA, SaxenaH. Non-invasive monitoring and assessment of phage therapy and phage targeting in bovine brucellosis employing a brucella- specific biomarker. Acta Scientific Microbiology, 2020b;3:59–68; doi: 10.31080/ASMI.2020.03.0678
42.
MorenoE, MoriyónI. The genus Brucella. The Prokaryotes, 2006; 5:315–456.
43.
NakaiH, IwakiY, KayMA, CoutoLB. Isolation of recombinant adeno-associated virus vector-cellular DNA junctions from mouse liver. J Virol, 1999; 73(7):5438–5447.
44.
NiethA, VerseuxC, BarnertS, et al.A first step toward liposome-mediated intracellular bacteriophage therapy. Expert Opin Drug Deliv, 2015; 12(9):1411–1424.
45.
NtirandekuraJ-B, MatembaLE, KimeraSI, et al.Association of brucellosis with abortion prevalence in humans and animals in Africa: A review. African J Reproductive Health, 2018; 22:120–136.
46.
PalM, GizawF, FekaduG, et al.Public health and economic importance of bovine Brucellosis: An overview. Am J Epidemiol, 2017; 5:27–34.
47.
PappasG, PapadimitriouP, AkritidisN, et al.The new global map of human brucellosis. The Lancet Infectious Diseases, 2006; 6(2):91–99.
48.
PayneRJ, JansenVA. Understanding bacteriophage therapy as a density-dependent kinetic process. J Theor Biol, 2001; 208(1):37–48.
49.
PirisiA. Phage therapy—advantages over antibiotics? The Lancet, 2000; 356(9239):1418.
50.
PirnayJ-P, BlasdelBG, BretaudeauL, et al.Quality and safety requirements for sustainable phage therapy products. Pharm Res, 2015; 32(7):2173–2179.
51.
QuinnPJ, MarkeyBK, LeonardFC, et al.2011. Veterinary Microbiology and Microbial Disease, John Wiley & Sons.
52.
SergueevKV, FilippovAA, NikolichMP. Highly sensitive bacteriophage-based detection of Brucella abortus in mixed culture and spiked blood. Viruses, 2017; 9(6):144.
53.
SherasiyaR. 2024. Global prevalence of human brucellosis: A systematic review and meta-analysis; doi: 10.21203/rs.3.rs-4929733/v1
54.
SinghB, DhandNK, GillJ. Economic losses occurring due to brucellosis in Indian livestock populations. Prev Vet Med, 2015; 119(3–4):211–215.
55.
SkurnikM, StrauchE. Phage therapy: Facts and fiction. Int J Med Microbiol, 2006; 296(1):5–14.
56.
SybesmaW, PirnayJ-P, AlavidzeZ, et al.Silk route to the acceptance and re-implementation of bacteriophage therapy. Biotechnology J, 2016; 11:595–600.
57.
TuonFF, GondolfoRB, CerchiariN. Human-to-human transmission of brucella- a systematic review. Trop Med Int Health, 2017; 22(5):539–546; doi: 10.1111/tmi.12856
58.
Van LeeuwenWB, RazaviED, KazemiS, AghaeeBL. Combination of bacteriophage and antibiotic therapy to control antimicrobial drug resistance bacterial infections: The evolutionary trade-off mechanism. Rev Res Medical Microbiol, 2024; 10(1097).
59.
VázquezR, Díez-MartínezR, Domingo-CalapP, et al.Essential topics for the regulatory consideration of phages as clinically valuable therapeutic agents: A perspective from Spain. Microorganisms, 2022; 10(4):717.
60.
VerbekenG, PirnayJ-P, LavigneR, et al.Call for a dedicated European legal framework for bacteriophage therapy. Arch Immunol Ther Exp (Warsz), 2014; 62(2):117–129.
61.
WangI-N, SmithDL, YoungR. Holins: The protein clocks of bacteriophage infections. Annual Rev Microbiol, 2000; 54:799–825.
XiaoYU, LiM, GuoX, et al.Inflammatory mechanism of brucella infection in placental trophoblast cells. Int J Mol Sci, 2022; 23(21); doi: 10.3390/ijms232113417
64.
ZhangJ, GuoF, HuangX, et al.A novel Omp25-binding peptide screened by phage display can inhibit Brucella abortus 2308 infection in vitro and in vivo. J Med Microbiol, 2014; 63(Pt 6):780–787.
65.
ZhangM, ZhangT, YuM, et al.The life cycle transitions of temperate phages: Regulating factors and potential ecological implications. Viruses, 2022; 14(9):1904.
66.
ZinsstagJ, SchellingE, RothF, et al.Human benefits of animal interventions for zoonosis control. Emerg Infect Dis, 2007; 13(4):527–531.
